PROMINENT Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes

Brief description of study

The purpose of this study is to find out if of K-877 (also called pemafibrate), the study drug, compared to placebo (a treatment which looks like the medicine but contains no active pemafibrate), lowers cardiovascular (CV) complications (also referred to as “events”), such as heart attack, stroke, and death from these conditions, in adults with type-2 diabetes mellitus (T2D) who have elevated triglycerides (TGs; one type of fat), and low high-density lipoprotein cholesterol (HDL-C; “good” cholesterol). The study will also test whether the study drug has other possible benefits in patients with diabetes, and will test the safety of the study drug. To answer these questions, it is important for patients to be in the study until the end even if they stop taking the study drug earlier.


Clinical Study Identifier: s18-01948
ClinicalTrials.gov Identifier: NCT03071692
Principal Investigator: Joshua R Deleon.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.